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LETTER TO THE EDITOR
Development of Acute Vogt–Koyanagi–Harada-like
Syndrome during the Treatment Course with
Vemurafenib for Metastatic Melanoma
Atitaya Apivatthakakul, MD1, Paradee Kunavisarut, MD1, Aniki Rothova, MD, PhD2, and Kessara
Pathanapitoon, MD, PhD 1
1Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand and
2Department of Ophthalmology, Erasmus Medical Centre, Rotterdam, The Netherlands
ABSTRACT
Purpose: To report on ocular Vogt–Koyanagi–Harada (VKH)-like syndrome under vemurafenib treatment for
metastatic melanoma.
Design: A case report.
Method: Description of clinical and imaging manifestations including fundus photography, fluorescein, and
indocyanine green angiography.
Results: A 46-year-old Thai female was diagnosed with metastatic melanoma of the skin and had been treated
with multiple surgical excisions, radiotherapy, and vemurafenib (initial dose 480 mg orally twice daily,
subsequently increased to maximum dose of 960 mg twice daily). After 6 months of vemurafenib use, she
complained of bilateral redness and photophobia and was diagnosed with bilateral anterior uveitis, which was
topically treated. Two weeks later, her visual acuity (VA) sharply deteriorated to 20/80 and counting fingers.
Ocular examination at that stage stronly resembled acute VKH disease. She exhibited intraocular inflammation,
and her fundus examination revealed bilateral optic disc swelling and serous retinal detachment. Fluorescein
angiogram showed disc leakage and multiple pinpoint hyperfluorescence leakage spots and indocyanine green
demonstrated multiple hypofluorescent spots. Oral prednisolone 30 mg/day was commenced while vemur-
afenib medication was ceased. Three weeks later, her vision improved, and serous retinal detachment subsided.
However, her cutaneous melanoma recurred.
Conclusions: Vemurafenib, a potential adjunct treatment for metastatic melanoma, was complicated by the
development of panuveitis, papillitis, and multiple serous detachments. These ocular symptoms were similar
to the presentation of acute VKH syndrome.
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Approximately half of cutaneous melanomas have
a mutation in the BRAF gene, with V600E being the
most common mutation, resulting in unchecked cell
proliferation and increase of melanoma cell survival.
In 2011, treatment of metastatic melanoma changed
with the introduction of the targeted cancer therapy
“BRAF inhibitors.” Several studies have shown
reduction in mortality rate and tumor progression
with BRAF inhibitors.1 Vemurafenib, a selective and
potent inhibitor of BRAF, was the first drug, which
demonstrated the improvement of overall and
progression-free survival.
The vast majority of BRAF mutations cause the
activation of the mitogenic protein kinase (MEK),
while vemurafenib interrupts a step on BRAF/MEK
pathway and also affects immune system by modify-
ing various cytokine production. Previously reported
systemic side effects of vemurafenib include rash,
arthralgia, photosensitivity, fatigue, nausea, diarrhea,
squamous cell carcinoma, and keratoacanthoma of the
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skin.1 In this case report, we report on a patient with
metastatic cutaneous melanoma who developed signs
of acute ocular Vogt–Koyanagi–Harada (VKH)-like
syndrome during the treatment course of vemurafenib
administration.
CASE REPORT
A 46-year-old Thai female was diagnosed with cuta-
neous melanoma at her right toe in February 2017 and
has undergone several surgical excisions together with
postoperative radiotherapy; however, these regimens
could not control the melanoma progression. The mel-
anoma continuously spread to her right thigh and groin.
Since she has been BRAF mutation positive, she
received the novel treatment modality with vemurafe-
nib (initial dose 480 mg orally twice daily and increased
to maximum dose of 960 mg orally twice daily for
6 months). After 6 months of vemurafenib treatment,
she presented with acute anterior uveitis of her both
eyes and was treated topically. Fundus examinations
at that timewere normal. After twoweeks, she reported
back with deteriorated visual acuity (VA) of 20/80 in
OD and counting fingers in OS. She also complained of
headaches, nausea, and tinnitus. Eye examination
showed 3+ cells in anterior chamber and 2+ vitreous
cells. Fundus examination revealed bilateral serous ret-
inal detachment with choroidal folds and optic disc
edema (Figure 1A, B). Optical coherence tomography
showed subretinal fluid, which correlated with exuda-
tive detachment, choroidal thickening, and peripapil-
lary subretinal fluid accumulation (Figure 1E, F).
Fundus fluorescein angiogram showed multiple hyper-
fluorescent pinpoint spots with leakage together with
disc leakage and subretinal pooling of fluorescein in the
area of exudative retinal detachment (Figure 1C, D).
Indocyanine green angiogram showed vascular leakage
of choroid with late-phase multiple hypofluorescent
dots. Ultrasonography showed choroidal thickening.
The results of laboratory investigations, which included
complete blood counts, venereal disease research
laboratory test, treponema pallidum hemagglutination,
human immunodeficiency virus antibody, tuberculin
skin test, and chest X-ray, were all within the normal
limits or negative. She was initially treated with oral
prednisolone 60 mg/day (1 mg/kg/day), but due to
multiple side effects, the dose was quickly tapered
down to 30 mg/day together with posterior subtenon
triamcinolone injection in both eyes while vemurafenib
was withdrawn. Oral prednisolone was gradually
tapered to 20 mg/day. Her vision was improved in
4 weeks. Ten weeks after vemurafenib was withdrawn,
the inflammation has subsided, and visual acuities
improved to 20/30 OD and 20/40 OS. Unfortunately,
her cutaneous melanoma recurred, and she had under-
gone further surgical excisions. Eight weeks after
cessation of vemurafenib, she was diagnosed with
brain metastasis.
DISCUSSION
We report on a patient with metastatic cutaneous
melanoma, who developed panuveitis compatible
with the diagnosis of acute VKH-like syndrome
under vemurafenib therapy. Previously reported ocu-
lar complications related to vemurafenib medication
included anterior uveitis, uveitic macular edema, and
panuveitis; however, most of these reports were
restricted to the anterior segment inflammation and
responded well to topical corticosteroids.2 Our
patient, however, demonstrated features that were
similar to the acute phase of VKH disease.
VKH disease is a multisystem inflammatory disease
characterized by bilateral panuveitis with serous retinal
detachment. It is ascribed to an autoimmune inflamma-
tory reaction mediated by T-cells that target melanocyte
in individuals susceptible to the disease and is often
associated with skin, central nervous system, and audi-
tory abnormalities. VKH-like development in melanoma
patients was noted earlier, occurring after immunother-
apy tumor-infiltrating lymphocytes and even after
a surgical excision of metastatic melanoma.1 Donaldson
et al. noted the presence of uveitis and vitiligo after
bacillus Calmette–Guerin therapy for melanoma.3 The
frequent occurrence of serous retinopathy after the use
of vemurafenib and other BRAF inhibitors was repeat-
edly reported, however typically without any signs of
intraocular inflammation.4 Other newer anti-melanoma
drugs including dabrafenib and trametinib were also
associated with the development of the VKH-like syn-
drome, manifesting ocular, skin, and hearing manifesta-
tions. Whether to discontinue treatment in patients with
drug-induced uveitis is controversial and remains an
individual decision. Based on Cancer therapy Common
Terminology Criteria for Adverse Events (CTCAE), our
patient was classified as a grade 4 ocular adverse event
(panuveitis with VA of less than 20/200) and vemurafe-
nib was withdrawn. In contrast, continuation of BRAF
inhibitors or a dosage adjustment can be performed in
patients with mild ocular side effects and a beneficial
reaction to topical medication.
The exact cause of VKH-like ocular signs during
BRAF therapy is not yet entirely explained, and several
hypotheses have been postulated. First, the ocular
inflammation may be caused by systemic over-
sensitization tomelanocytic antigen during the treatment
period as vemurafenib has a strong antitumor effect
leading to massive apoptosis and death of melanocytes.
Another hypothetical explanation might involve shared
pathogenetic pathways common to skin melanoma and
VKH disease, such as specific HLA types. Fujimura et al.
reported the association betweenmelanoma patients and
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HLA-DRB1*04:05, which is also strongly associated with
VKH disease.5 In summary, vemurafenib is one of the
life-prolonging medications for patients with metastatic
melanoma but might be associated with ocular side
effects ranging from mild to severe inflammation. The
discontinuation of this valuable drug should be based on
the severity of adverse effects. Further studies are needed
to evaluate the potential treatment options for severe
ocular adverse events.
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